Activation of Phospholipase C-beta 1 via Galpha q/11 during Calcium Mobilization by Calcitonin Gene-related Peptide*

Hicham DrissiDagger , Françoise LasmolesDagger , Véronique Le Mellay§, Pierre J. MarieDagger , and Michèle Lieberherr§

From the Dagger  Institut National de la Santé et de la Recherche Médicale, U 349, Hôpital Lariboisière, Paris, and the § Centre National de la Recherche Scientifique, UPR 1524, Jouy-en-Josas, France

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Interaction of calcitonin gene-related peptide (CGRP) with its receptors leads to stimulation of adenylyl cyclase and/or phospholipase C (PLC). While regulation of adenylyl cyclase is thought to involve the G-protein Gs, it is not known whether activation of PLC results from coupling the receptor to Gq family proteins or whether beta gamma subunits released from receptor-activated Gs activate PLC. We used human bone cells OHS-4 bearing CGRP receptors in which CGRP activates only the PLC signaling pathway to determine how CGRP acts. CGRP increased the concentration of intracellular calcium ([Ca2+]i) within 5 s via a Ca2+ influx through voltage-gated calcium channels and by mobilizing calcium from the endoplasmic reticulum. The activation of effectors, like PLC coupled to G-proteins, is the early event in the pathway leading to inositol 1,4,5-trisphosphate formation, which is responsible for Ca2+ mobilization. Western blotting demonstrated a range of PLC-beta isoforms (beta 1, beta 3, beta 4, but not beta 2) and G-proteins (Galpha q/11 and Galpha s). Only phospholipase C-beta 1 is involved in the mobilization of Ca2+ from the endoplasmic reticulum of Fura-2-loaded confluent OHS-4 cells and the formation of inositol 1,4,5-trisphosphate by CGRP; PLC-gamma have no effect. Activation of PLC-beta 1 by CGRP involves the Galpha q/11 subunit, which is insensitive to pertussis toxin, but not Gbeta gamma subunits. We therefore believe that CGRP causes the activation of two separate G-proteins.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Calcitonin gene-related peptide (CGRP)1 is a 37-amino acid peptide generated by alternative splicing of the calcitonin/CGRP gene product (1, 2), which effects numerous organs, including bone (3). The receptor for CGRP, which belongs to a subgroup of G-protein-coupled receptors (4-6), is a seven-transmembrane domain receptor protein, very like other receptors of the subfamily (7, 8). The binding of CGRP to these receptors activates multiple signaling pathways. The main signal pathway used by CGRP is the adenylyl cyclase pathway (9-14), but CGRP has also been reported to activate guanylate cyclase (15, 16) and phospholipase C (17) and to increase the intracellular calcium concentration (18). However, in osteoblastic OHS-4 cells, which possess CGRP receptors (19), CGRP does not stimulate adenylyl cyclase as do other cell types (20, 21), but it does increase intracellular calcium. This suggests that the CGRP receptor activates different G-proteins than do other calciotropic peptide hormones (22).

There are many similar heterotrimeric G-proteins that transduce a signal from a hormone-bound receptor to a variety of downstream effector molecules (23-25). Mammals have several types of G-proteins, which form the alpha  subunit and the beta  and gamma  subunits. These include the Gq, Gs, Gi/Go, and G12 subfamilies, which are classified on the basis of amino acid sequence of the alpha  subunits. G-proteins are also divided traditionally into two types based on their sensitivity to Bordetella pertussis toxin (PTX) (26). The PTX-sensitive G-proteins are inactivated by ADP-ribosylation of the alpha  subunit. This group includes members of the Gi and Go subfamily. Gs- and Gi-proteins were originally purified as mediators of adenylyl cyclase pathway (27). PTX-insensitive G-proteins are resistant to ADP-ribosylation and include members of the Gq subfamily (27). The alpha  subunits of these proteins activate phospholipase C-beta isoenzymes (28), but not phospholipases (PLCs) Cgamma or Cdelta (29-33). PLC-beta isoenzymes may be stimulated by both G-protein alpha  subunits of the Gq family and by free beta gamma subunits (34-36).

PLC can thus be stimulated via receptors with the dual signaling properties described above. Binding of the ligand to the receptor either stimulates adenylyl cyclase via Galpha s, and phospholipase C is activated by beta gamma subunits released from activated Gs, or the receptor couples to multiple G proteins leading to the activation of adenylyl cyclase and PLC via Gs and alpha  subunits of the Gq family (37). The latter route appears to apply to the human TSH receptor (38), and the turkey erythrocyte beta -adrenergic receptor (39). The present study identifies and characterizes the PLC isoform involved in the mobilization of Ca2+ from the endoplamic reticulum and inositol 1,4,5 trisphosphate formation of bone OHS-4 cells in response to CGRP, and its regulation by G-protein alpha  and beta gamma subunits.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- The ECL kit, and L-3-phosphatidyil [2-3H]inositol 4,5-bisphosphate and Fura-2/AM were purchased from Amersham, Life Technology (Les Ulis, France). Polyclonal rabbit anti-PLC antibodies to PLC-beta 1, PLC-beta 2, PLC-beta 3, and PLC-beta 4, polyclonal rabbit anti-G-protein antibodies to Galpha q/11, Galpha s, Galpha i, Gbeta , and Ggamma 1 and their blocking peptides were obtained from Santa Cruz Biotechnology, Inc. and Tebu (Le Perray-en-Yvelines, France). Peroxidase-conjugated goat anti-rabbit IgG was obtained from Bio-Rad (Ivry-sur-Seine, France). Human CGRP and all chemicals were purchased from Sigma (St. Quentin Fallavier, France). Dulbecco's modified Eagle's essential medium and fetal calf serum were supplied by Eurobio (Les Ulis, France).

Human Cell Culture-- The human bone cell line OHS-4, which exhibits most of the osteoblast phenotype (40), was kindly provided by Drs. B. Fournier and P. Price. Cells were grown on rectangular glass coverslips or in Petri dishes (100 cm2) for 4 days in Dulbecco's modified Eagle's essential medium supplemented with 10% heat-inactivated fetal calf serum. Cells were then incubated for 72 h in Dulbecco's modified Eagle's essential medium containing 1% heat-inactivated fetal calf serum and transferred to serum-free medium 24 h before use.

Calcium Measurement and Experimental Protocol-- The cells were washed with Hank's HEPES, pH 7.4 (137 mM NaCl, 5.6 mM KCl, 0.441 mM KH2PO4, 0.442 mM Na2HPO4, 0.885 mM MgSO4·7H2O, 27.7 mM glucose, 1.25 mM CaCl2 and 25 mM HEPES), and loaded with 1 µM Fura-2/AM for 30 min in the same buffer at room temperature. The glass coverslip supporting the cells was inserted into a cuvette containing 2.5 ml of Hank's HEPES, pH 7.4. The cuvette was placed in a thermostatically controlled (37 °C) Hitachi F-2000 spectrofluorimeter. Drugs and reagents were added directly to the cuvette with continuous stirring. The Fura-2 fluorescence response to the intracellular calcium concentration ([Ca2+]i) was calibrated from the ratio of the 340/380-nm fluorescence values after subtraction of the background fluorescence of the cells at 340 and 380 nm as described by Grynkiewicz et al. (41). The dissociation constant for the Fura-2-Ca2+ complex was taken as 224 nM. The values for Rmax and Rmin were calculated from measurements using 25 µM digitonin and 4 mM EGTA and enough Tris base to raise the pH to 8.3 or higher. Each measurement on Fura-2-loaded cells was followed by a parallel experiment under the same conditions with cells not loaded with Fura-2.

We first studied the direct effects of CGRP (0.1-100 nM) on [Ca2+]i in OHS-4 cells. We then investigated whether the effects of CGRP on [Ca2+]i were due to an influx of Ca2+ from the extracellular milieu and/or Ca2+ mobilization from intracellular stores. Two types of blocking experiments were performed. One involved adding a small excess of EGTA (2 mM), a chelator of extracellular calcium, to the medium in the cuvette and incubating for 30 s before adding CGRP. The second involved blocking of L-type Ca2+ channels with 1 µM nifedipine and verapamil. We investigated how much of the transient increase in [Ca2+]i was due to Ca2+ release from the endoplasmic reticulum using neomycin, which inhibits PLC by binding to phosphoinositides (42), and U-73122, which directly inhibits the PLC involved in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (43). We then determined whether different PLC-beta isoenzymes are involved in the effects of CGRP by incubating OHS-4 cells for 5 min with 20 µg/ml saponin plus excess anti-PLC antibody, anti-G-protein antibody, or nonimmune rabbit serum (44). Cells were washed twice to remove saponin and incubated with the anti-PLC antibody, anti-G-protein antibody, or nonimmune rabbit serum for 1 h at 37 °C. 1 µM Fura-2/AM was added for the last 20 min of incubation. In some experiments, anti-PLC-beta 1 antibody and anti-Galpha q/11 antibody were set up in competition with the antigen against which they were produced, or with the antigens corresponding to the other anti-PLC antibodies for 2 h at room temperature (antibody:peptide 1:10 or 1:100, according to the specifications of the manufacturer), prior to use. CGRP was used at the concentration that gave the greatest increase in [Ca2+]i in confluent OHS-4 cells. The G-protein involved in the activity of CGRP was identified by incubating the cells with 100 ng/ml PTX for 16 h. Fura-2/AM loading and [Ca2+]i measurements were carried out with the toxin.

Cell Homogenates and Membranes-- Cells were washed three times with ice-cold phosphate-buffered saline, pH 7.4, and scraped off into ice-cold extraction buffer (20 mM Tris-HCl, pH 7.5, 0.5 mM EGTA, 2 mM EDTA, 0.6 mM pepstatin, 0.5 mM benzamidine, 0.1 mM leupeptin, 2 mM phenylmethylsulfonyl fluoride, 0.125 mM aprotinin, and 1 mM dithiothreitol). They were sonicated on ice twice for 20 s each at 40 KHz, and the homogenate was centrifuged for 10 min at 600 × g to remove nuclei. The supernatant was centrifuged at 100,000 × g for 1 h. The resulting membrane pellets were resuspended in homogenizing buffer, and aliquots of the total homogenate and membrane fractions were stored at -80 °C. Protein was determined by the method of Bradford (45) with bovine serum albumin as a standard.

Protein Separation and Immunoblotting-- Proteins were separated by SDS-PAGE (7.5% resolving gel for PLC and 13% for G-protein) in 25 mM Tris base, pH 8.3, 192 mM glycine, 0.1% SDS (46). They were electrophoretically transferred to nitrocellulose membranes (Immobilon P, Millipore, St. Quentin-en-Yvelines, France) in the same buffer with 20% ethanol for 2 h at 100 V (47). Nonspecific binding to nitrocellulose was prevented by incubating the membranes in 50 mM Tris-buffered saline (TBS) pH 7.5 containing 150 mM NaCl, 5% skimmed milk powder and 0.05% Tween-20 for 12 h at 4 °C. The membranes were washed in TBS containing 0.1% Tween-20 and incubated overnight at 4 °C with polyclonal rabbit antibodies against specific isoenzymes of PLC (PLC-beta 1, PLC-beta 2, PLC-beta 3, and PLC-beta 4) and specific G-proteins (Galpha q/11, Galpha s). The concentrations of PLC antibodies in TBS, 1.5% skimmed milk, 0.1% Tween 20 were as follows: 0.1 µg/ml for PLC-beta 1, 0.5 µg/ml for PLC-beta 2, 1 µg/ml for PLC-beta 3, and 0.5 µg/ml for PLC-beta 4. The concentrations of Galpha q/11 and Galpha s antibodies in the same buffer were 0.2 µg/ml and 0.5 µg/ml, respectively. The antibodies bound to the proteins on the nitrocellulose were detected using peroxidase-conjugated goat anti-rabbit IgG (1 mg/ml) (diluted 1/5000 in TBS, 1.5% skimmed milk, 0.1% Tween 20). The antigen was detected by enhanced chemiluminescence. Molecular size standards were used to estimate the apparent molecular mass of the PLC, myosin, 199 kDa; beta -galactosidase, 120 kDa; bovine serum albumin, 87 kDa; and ovalbumin, 48 kDa. The molecular size standards for G-proteins were phosphorylase B, 105 kDa; bovine serum albumin, 82 kDa; ovalbumin, 49 kDa; carbonic anhydrase, 33.3 kDa; soybean trypsin inhibitor, 28.6 kDa; and lysozyme, 19.4 kDa.

Phosphatidylinositol 4,5-Bisphosphate Hydrolysis Assay-- Phospholipid vesicles were prepared as described by Hofmann and Majerus (48), and assays were done essentially as described by Wu et al. (49). Diluted membranes (10 µl, 5-10 µg of protein) in 50 mM HEPES, pH 7.0, 0.5 mM EGTA, 2 mM EDTA, 0.6 mM pepstatin, 0.5 mM benzamidine, 0.1 mM leupeptin, 2 mM phenylmethylsulfonyl fluoride, 0.125 mM aprotinin, and 1 mM dithiothreitol, were added to 40 µl of assay buffer (50 mM HEPES, pH 7.0, 100 mM NaCl, 5 mM MgCl2, 0.6 mM CaCl2, and 2 mM EGTA) plus 10 µl of PIP2 (10,000-12,000 cpm of [3H]PIP2), and incubated on ice for 10 min. For the antibody inhibition assay, membranes were incubated for 2 h with 10 µl of antibody, at the concentrations indicated, prior to adding the reaction mixture. For competition assay with the peptide control, 10 µl of the antibody to be tested were mixed with 2 µl of serially diluted peptide control before adding to the membranes and incubation for 2 h. The reaction was started by adding GTPgamma S with or without CGRP, followed by incubation at 37 °C for 15 min. The reaction was stopped by adding 0.5 ml of chloroform/methanol/HCl (40:20:0.5), mixing, and chilling on ice. Soluble inositol phosphates (indicating PIP2 hydrolysis) were extracted by adding 150 µl of chloroform and 200 µl of 0.1 M HCl. Phases were separated by centrifugation, and 200 µl of the upper aqueous phase were taken for liquid scintillation counting.

Statistical Analysis-- The data were analyzed by one-way analysis of variance. Treatment pairs were compared by Dunnett's method. A value of n indicates the number of glass coverslips used for a specific experiment or the number of cultures.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Direct Effects of CGRP on Intracellular Calcium Concentration-- The basal intracellular calcium concentration in confluent OHS-4 cells was 115 ± 5 nM (mean ± S.E., n = 18). The transient increase in [Ca2+]i induced by 1 nM CGRP formed a sharp peak which fell rapidly after 15 s, but remained above the basal level (plateau phase) (25 ± 2%, mean ± S.E., n = 6, p < 0.001) (Fig. 1A). The concentration-dependent effects of CGRP were bell-shaped, with a maximum activity at 1 nM (Fig. 1B).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of CGRP on the intracellular calcium concentration in confluent OHS-4 cells. A, direct effect of 1 nM CGRP on intracellular calcium. These results are representative of eight different coverslips. B, dose-dependent effects of CGRP on intracellular calcium. Intracellular Ca2+ concentrations were determined at 10 s. Values are means ± S.E., n = 8, and are significantly different from the basal level. ¥p < 0.01 and *p < 0.001.

Mechanisms of CGRP-induced Changes in Intracellular Calcium Concentration-- 1 nM CGRP was added 30 s after 2 mM EGTA, or 60 s after 1 µM nifedipine or 1 µM verapamil. Verapamil itself caused a small (5%) decrease in [Ca2+]i, whereas nifedipine caused a small (5%) transient increase (43). EGTA, nifedipine, and verapamil reduced the magnitude (50 ± 10%, mean ± S.E., n = 8, p < 0.001) of the transient peak induced by CGRP, and the plateau phase was completely abolished (Fig. 2A; data shown only for EGTA and nifedipine).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Mechanisms of CGRP actions on intracellular calcium in confluent OHS-4 cells. A, cells were incubated for 30 s with 2 mM EGTA or for 60 s with 1 µM nifedipine before adding 1 nM CGRP. EGTA and nifedipine both reduced the transient peak and abolished the plateau phase. B, cells were incubated for 3 min with 1 mM neomycin or 60 s with 3 µM U-73122 before adding 1 nM CGRP. Neomycin and U-73122 both abolished the transient peak and had no effect on the plateau phase. These results are representative of eight different coverslips for each experiment.

Cells were incubated for 3 min with 1 mM neomycin, with 3 µM U-73122 or with 2 µM U-73343, a closed analog of U-73122 but inactive agent (43), before adding 1 nM CGRP. Neomycin itself caused a small (5%) decrease in [Ca2+]i (44), whereas U-73122 caused a small (5%) increase (43). Neomycin and U-73122 both abolished the transient peak, but not the plateau phase (Fig. 2B). U-73343 (0.3-5 µM) had no effect on the intracellular calcium response to CGRP (data not shown).

The cells incubated for 16 h with 100 ng/ml PTX showed no change in the basal level of [Ca2+]i or in the [Ca2+]i response to 1 nM CGRP (Fig. 3).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of Pertussis toxin on the intracellular calcium response to CGRP in confluent OHS-4 cells. Cells were incubated for 16 h with 100 ng/ml PTX. Fura2/AM loading and calcium measurement were done in the presence of PTX. PTX had no effect on the CGRP-induced increase in intracellular calcium. These results are representative of at least six coverslips.

Western Immunoblotting of the PLC and G-proteins-- All the anti-PLC-beta antibodies used in this study were raised against amino acid sequences in the carboxyl terminus of each PLC-beta . Western immunoblotting showed a 150-kDa immunoreactive band using the anti-PLC-beta 1 antibody, a 158-kDa immunoreactive band using the anti-PL-beta 3 antibody, and a 153-kDa immunoreactive band using the anti-PLC-beta 4 antibody (Fig. 4). No immunoreactive reactive band for PLC-beta 2 was found (Fig. 4). Immunoblots probed with the anti-Galpha q/11 antibody or the anti-Galpha s antibody showed a 42-kDa immunoreactive band (Fig. 5). A competitive Western blot with polyclonal PLC-beta 1, PLC-beta 3, and PLC-beta 4 antibodies and the antigens against which they were raised showed that immunoreactivity was completely abolished when a 100-fold excess of antigen was included (data not shown). This also shows that each antibody reacted with the intended target isoform.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 4.   PLC isoforms in confluent OHS-4 cells. Cell homogenates were prepared as described, and 35-µg aliquots were separated by electrophoresis on SDS-polyacrylamide gel, transferred to nitrocellulose membranes, and probed with antibodies against the various PLC-beta isoforms (arrows). The concentrations of anti-PLC antibodies were 0.1 µg/ml for PLC-beta 1, 0.5 µg/ml for PLC-beta 2, 1 µg/ml for PLC-beta 3, and 0.5 µg/ml for PLC-beta 4. Lines indicate the molecular masses of the standards (Std) from top to bottom: myosin, 199 kDa; beta -galactosidase, 120 kDa; bovine serum albumin, 87 kDa; and ovalbumin, 48 kDa.


View larger version (59K):
[in this window]
[in a new window]
 
Fig. 5.   G-proteins in confluent OHS-4 cells. Aliquots (20, 30, and 50 µg) of each homogenate were separated by electrophoresis on SDS-polyacrylamide gel, transferred to nitrocellulose membranes, and probed with antibodies against various alpha  subunits of G-proteins (arrows). The concentrations of anti-Galpha q/11 and anti-Galpha s antibodies were 0.2 µg/ml and 0.5 µg/ml, respectively. Lines indicate the molecular masses of the standards from top to bottom: phosphorylase B, 105 kDa; bovine serum albumin, 82 kDa; ovalbumin, 49 kDa; carbonic anhydrase, 33.3 kDa; and soybean trypsin inhibitor, 28.6 kDa.

PLC Isoenzymes and G-proteins Involved in the Effects of CGRP on Intracellular Calcium-- Treament of the cells with saponin for 5 min followed by incubation for 60 min with the anti-PLC antibody or anti-G-protein antibody in the absence of saponin did not affect the basal [Ca2+]i. Nonimmune serum had no effect on basal [Ca2+]i or on the [Ca2+]i response to CGRP.

The CGRP-induced increase in [Ca2+]i was reduced by anti-PLC-beta 1 antibody, whereas antibodies to PLC-beta 3 and PLC-beta 4 had no effect (Fig. 6). The residual increase was due to Ca2+ influx because it was totally blocked by incubating the cells with 2 mM EGTA. Anti-PLCgamma 1 and anti-PLCgamma 2 antibodies had no effect on the [Ca2+]i response to CGRP (Fig. 6), as did anti-PLC-beta 2 antibody (data not shown).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 6.   Responses of OHS-4 cells treated with antibodies against PLC isoforms to CGRP. Cells were cultured, loaded with Fura2/AM, and incubated with PLC antibodies as described. The concentrations of anti-PLC antibodies were 1 µg/ml for PLC-beta 1, 10 µg/ml for PLC-beta 3, 5 µg/ml for PLC-beta 4, 10 µg/ml for PLC-gamma 1, and 10 µg/ml for PLC-gamma 2. Only anti-PLC-beta 1 antibody blocked Ca2+ mobilization induced by CGRP. In some experiments, CGRP was added 30 s after 2 mM EGTA. These results are representative of at least six coverslips for each experimental case.

Polyclonal anti-PLC-beta 1 antibody was incubated for 2 h with its corresponding antigen or with the antigens used to produce the other anti-PLC antibodies (antibody:antigen 1:10 or 1:100) before use. The inhibition of the CGRP-induced increase in [Ca2+]i due to anti-PLC-beta 1 antibody totally disappeared only when the anti-PLC-beta 1 antibody was incubated with its own antigen, but not with the antigens used to raise the other anti-PLC antibodies (Fig. 6; data shown only for the antigen corresponding to PLC-beta 1).

The CGRP-induced transient peak in [Ca2+]i was blocked by anti-Galpha q/11 antibody (Fig. 7). The residual increase was due to a Ca2+ influx because this was totally blocked by incubating the cells with 2 mM EGTA (Fig. 7). The anti-Galpha i antibody (1 µg/ml), which cross-reacts with Galpha i1, Galpha i2, and Galpha i3, and anti-Galpha s antibodies did not alter the [Ca2+]i response to CGRP (Fig. 7). Adding the anti-Gbeta antibody, which reacts with Gbeta 1, Gbeta 2, Gbeta 3, and Gbeta 4, and the anti-Ggamma antibody to the cell had no effect on the [Ca2+]i response to CGRP (Fig. 7).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 7.   Responses of OHS-4 cells treated with antibodies against G-proteins to CGRP. Cells were cultured, loaded with Fura2/AM, and incubated with G-protein antibodies as described. The concentrations of anti-G-protein antibodies were 2 µg/ml for Galpha q/11, 5 µg/ml for Galpha s, 5 µg/ml for Galpha i, and 5 µg/ml for Gbeta plus 5 µg/ml for Ggamma . Only anti-Galpha q/11 antibody blocked Ca2+ mobilization induced by CGRP. These results are representative of at least six coverslips for each experimental case.

PIP2 Hydrolysis-- Since testing the effect of GTPgamma S on intracellular calcium needed permeabilized cells, and this made it impossible to keep the antibodies inside the cell, we used a cell-free membrane system to test the activity of the antibodies. OHS-4 membranes containing endogenous PLC and G subunits were mixed with phospholipid vesicles containing radioactive substrate ([3H]PIP2). Fig. 8A shows the effect of CGRP on the hydrolysis of PIP2 in the absence of GTPgamma S. The effect of GTPgamma S in the absence and presence of 1 nM CGRP showed that GTPgamma S was ineffective below 1 µM (Fig. 8B). GDPbeta S (100 µM) inhibited the increase induced by 10 µM GTPgamma S, 10 µM GTPgamma S plus 1 nM CGRP, or 1 nM CGRP alone (data not shown). OHS-4 membranes were incubated with antibodies prior to stimulation with 100 µM GTPgamma S. All anti-PLC antibodies (beta 1, beta 3, and beta 4), like anti-Galpha q/11 and anti-Gbeta gamma antibodies, inhibited the PIP2 hydrolysis induced by GTPgamma S (Fig. 8C), whereas anti-Galpha s and anti-Galpha i antibodies had no effect (data not shown). Membranes incubated with both the antibody and the blocking peptide, gave the same amount of [3H]inositol 1,4,5-trisphosphate as obtained with preimmune serum (Fig. 8C).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 8.   Effects of anti-PLC and anti-G-protein antibodies on PIP2 hydrolysis induced by CGRP and/or GTPgamma S in OHS-4 membranes. A, direct effects of CGRP in the absence of GTPgamma S. B, effects of GTPgamma S on the hydrolysis of PIP2 in the absence or presence of 1 nM CGRP. C, 5 µg of OHS-4 membranes were incubated for 2 h with 1 µg/ml anti-PLC-beta 1 antibody or with anti-PLC-beta 1 plus 10 µg/ml peptide control. D, 5 µg of OHS-4 membranes were incubated for 2 h with 10 µg/ml anti-PLC-beta 3 antibody, 5 µg/ml anti-PLCbeta 4 antibody, 5 µg/ml anti-Gbeta antibody plus 5 µg/ml anti-Ggamma antibody or preimmune serum (PI) or with the antibody plus peptide control used at 10 times the concentration used for the antibody. PIP2 hydrolysis was performed in the presence or absence of 100 µM GTPgamma S. The PIP2 hydrolysis in control incubations with GTPgamma S and without membranes was subtracted from all values. Hatched columns represent data obtained from incubating the antibody with its antigen prior to adding the membranes. Values are means ± S.E., n = 4, and are significantly different: A, from the basal level in the presence of CGRP, *p < 0.001; B, from the basal level in the presence of GTPgamma S or GTPgamma S plus CGRP, *p < 0.001; C, from the level of CGRP, *p < 0.001 or from the level of anti-PLC-beta 1 plus control peptide in the presence of CGRP, #p < 0.001; D, from the level of preimmune serum, *p < 0.001, or from the level in the presence of antibody, #p < 0.001.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We have shown that Galpha q/11-protein coupled to phospholipase C-beta 1 is involved in the signaling of CGRP in human bone cells, and that Gbeta gamma subunits have no effect. The data also indicate that Ca2+ mobilization from the endoplamic reticulum following the increased formation of inositol 1,4,5-trisphosphate induced by CGRP is due to activation of a Galpha q/11 that is insensitive to pertussis toxin.

CGRP increases intracellular calcium concentration within 5 s via two mechanisms. It causes an influx of Ca2+ from the extracellular milieu via voltage-gated calcium channels as indicated by the experiments with EGTA, nifedipine, and verapamil. This mechanism is different from that of rat osteoblastic UMR106 cells, in which depleting extracellular Ca2+ induces an efflux of intracellular Ca2+ involving KATP channels (18). Activating the membrane KATP channels with high concentrations of CGRP (100 nM) could inhibit transmembrane Ca2+ uptake by hyperpolarizing the membrane potential, so reducing the voltage-dependent Ca2+ channel activity (53). CGRP causes the release of Ca2+ from the endoplamic reticulum in human OHS-4 cells as it does in rat UMR106 cells (18). This seems to be a general mechanism of CGRP action.

The activation of phosphoinositide-specific phospholipase C-beta upon stimulation of specific cell receptors results in the formation of second messengers, diacylglycrol, a direct activator of protein kinase C, and inositol 1,4,5-trisphosphate (50, 51). The latter binds to receptors on the endoplasmic reticulum, causing a transient release of calcium from the endoplasmic reticulum. As activation of PLC-beta is an early event in the signal transduction pathway resulting in a variety of cellular responses, we first identified the PLC-beta isoforms in bone OHS-4 cells. We find several isoforms of PLC-beta , beta 1, beta 3, and beta 4 but no PLC-beta 2, which is present in the rat brain (52) and in rat osteoblasts (44). As confluent rat osteoblasts do not possess PLC-beta 4 (44), whereas this isoform is present in the brain (52), these isoenzymes may well have a tissue- and/or species-specific distribution.

The next step was to identify the PLC-beta isoform involved in the effect of CGRP. This is the first report that PLC-beta 1 is involved in mobilization of Ca2+ from the endoplasmic reticulum by CGRP. Anti-PLC-beta 1 antibody inhibits the CGRP-induced increase in [Ca2+]i in much the same way as direct (U-73122) or indirect (neomycin) inhibitors of PLC. Anti-PLC antibody, like PLC inhibitors, blocks only the part of the increase in [Ca2+]i that is due to Ca2+ mobilization from the endoplasmic reticulum. The inhibition of the enzyme activity by anti-PLC-beta 1 antibody is totally abolished in competition experiments, in which polyclonal PLC-beta 1 antibody is incubated with the antigen against which it was raised, but not when using the antigen corresponding to other PLC-beta . This type of enzyme inhibition by selective antibodies against phosphoinositide-specific PLC has also been demonstrated in fresh bovine erythrocytes (54) and rat osteoblasts (44), suggesting that the antibody directed against an amino acid sequence at the carboxyl terminus of the PLC-beta binds to a part of the enzyme which is critical for the geometry of the active site. Anti-PLC-beta 1 antibody also inhibits the formation of inositol 1,4,5-trisphoshate in a OHS-4 cell-free membrane system. Neither PLC-beta 3 and PLC-beta 4 are involved in CGRP signal transduction, although both PLC stimulate PIP2 hydrolysis in the presence of GTPgamma S. Similarly, PLC-gamma 1 and -gamma 2 take no part in the effects of CGRP as expected, because PLC-gamma are substrates for growth factor receptor protein-tyrosine kinases (55).

It is very likely that only PLC-beta is involved in the action of CGRP, as only PLC-beta types are regulated via heterotrimeric G-proteins in response to agonist binding to receptors (55, 56). Receptor activation of PLC via G-proteins occurs by pertussis toxin-sensitive and toxin-insensitive signaling pathways (26). The alpha  subunits of the Gq/11 family are presumed to mediate the toxin-insensitive pathway, but the nature of the G-proteins mediating the toxin-sensitive pathway is less well understood (55-58). This study shows that the PLC-beta 1 involved in the action of CGRP is linked to a pertussis toxin-insensitive G-protein, and this PTX-insensitive G-protein is a member of the Gq family. These results are consistent with the fact that the G-proteins Gq/11 are the most prominent G-protein activators in receptor-mediated regulation of the PLC-beta 1 (29). Moreover, forskolin does not mimic the effects of CGRP on [Ca2+]i,2 but increases cAMP formation in OHS-4 cells (19). Anti-Galpha i and anti-Galpha s antibodies do not block the [Ca2+]i response to CGRP or the stimulation of PIP2 hydrolysis induced by GTPgamma S. Gbeta gamma subunits, like PLC-beta 3, which is the preferred target effector for Gbeta gamma subunits (36), are not involved in Ca2+ mobilization induced by CGRP. These data indicate that the effects of CGRP on intracellular calcium in OHS-4 cells are not mediated via the G-protein linked to the cAMP pathway.

Activation of PLC via G-protein-coupled receptors requires higher ligand concentrations than for receptor-mediated adenylyl cyclase activation (22). But, we find that PLC is activated in OHS-4 cells at concentrations similar to those that increase cAMP in other systems.

Although the main second messenger produced in response to CGRP remains cAMP in various cell types, probably via Galpha s-protein, CGRP acts via the phospholipase C pathway and Galpha q/11 protein in human bone cells. The present data therefore strongly suggest that the dual signaling of CGRP is due to the activation of more than one G-protein, Galpha s for the cAMP pathway and Galpha q/11 for the PLC pathway (Fig. 9).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 9.   Signals generated by CGRP. A, diagram showing the proposed coupling of CGRP receptors to phospholipase C and adenylyl cyclase via pathway 1 (two different G-proteins) or via pathway 2 (one G-protein acting through its alpha  and beta gamma subunits). B, signaling pathway used by CGRP in human OHS-4 bone cells. CGRP uses pathway 1 since it activates phospholipase C-beta 1 via a pertussis-insensitive Galpha q/11 protein, the beta gamma subunits being ineffective.

    ACKNOWLEDGEMENTS

We thank Drs. B. Fournier and P. A. Price (Department of Biology, University of California, La Jolla, CA) for providing the human osteoblastic OHS-4 cell line. The English text was checked by Dr. Owen Parkes.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: CNRS UPR 1524, Bâtiment 221, Institut National de la Recherche Agronomique, 78 350 Jouy-en-Josas, France. Tel.: 33 1 34 65 20 64; Fax: 33 1 34 65 21 09; E-mail: lieberhe{at}diamant.jouy.inra.fr.

The abbreviations used are: CGRP, calcitonin gene-related peptide; PLC, phospholipase C; TBS, Tris-buffered saline; PTX, pertussis toxin; G-protein, guanine nucleotide-binding regulatory protein; GTPgamma S, guanosine 5'-O-3'-thiotriphosphateGDPbeta S, guanosine 5'-O-2'-thiodiphosphatePIP2, phosphatidylinositol 4,5,-bisphosphate.

2 H. Drissi, F. Lasmoles, V. Le Mellay, P. J. Marie, and M. Lieberherr, unpublished data.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Amara, S. G., Jones, V., Rosenfeld, M. G., Ong, E. S., and Evans, R. M. (1982) Nature 29, 240-249
  2. Rosenfeld, M. G., Mermod, J. J., Amara, S. G., Swanson, L. W., Sawachenko, D. E., Rivier, J., and Vale, W. E. (1983) Nature 304, 120-135[Medline] [Order article via Infotrieve]
  3. Deftos, L. J., and Ross, B. A. (1989) in Bone and Mineral Research, Annual 6 (Peck, W. A., ed), pp. 267-316, Elsevier, New York
  4. Aiyar, N., Rand, K., Elshourbagy, N. A., Zeng, Z., Adamou, J. E., Bergsma, D. J., and Li, Y. (1996) J. Biol. Chem. 271, 11325-11329[Abstract/Free Full Text]
  5. Han, Z.-Q., Coppock, H. A., Smith, D. M., Van Noorden, S., Makgoba, M. W., Nicholl, C. G., and Legon, S. (1997) J. Mol. Endocrinol. 18, 267-272[Abstract]
  6. Kapas, S., and Clark, A. J. (1995) Biochem. Biophys. Res. Commun. 217, 832-838[CrossRef][Medline] [Order article via Infotrieve]
  7. Lefkowitz, R. J., Cotechia, S., Samana, P., and Costa, T. (1993) Trends Pharmacol. Sci. 14, 303-304[CrossRef][Medline] [Order article via Infotrieve]
  8. Oliviera, L., Paiva, A. C. M., Sander, C., and Vriend, G. (1994) Trends Pharmacol. Sci. 15, 170-172[CrossRef][Medline] [Order article via Infotrieve]
  9. Poyner, D. E. (1992) Pharmacol. Ther. 56, 32-51
  10. Farley, J. R., Hall, S. L., and Herring, S. (1993) Metabolism 42, 97-104[Medline] [Order article via Infotrieve]
  11. Bjurholm, A., Kreicbergs, A., Schultzberg, M., and Lerner, U. H. (1992) J. Bone Miner. Res. 7, 1011-1019[Medline] [Order article via Infotrieve]
  12. Thiebaud, D., Akatsu, T., Yamashita, T., Suda, T., Noda, T., Martin, R. E., and Martin, T. J. (1991) J. Bone Miner. Res. 6, 1137-1142[Medline] [Order article via Infotrieve]
  13. Michelangeli, V. P., Findlay, D. M., Fletcher, A., and Martin, T. J. (1986) Calcif. Tissue Int. 39, 44-48[Medline] [Order article via Infotrieve]
  14. Vignery, A., and MacCarthy, T. L. (1996) Bone 18, 331-335[CrossRef][Medline] [Order article via Infotrieve]
  15. Gray, D. W., and Marshall, I. (1991) Br. J. Pharmacol. 107, 691-696[Abstract]
  16. Parsons, A. M., and Seybold, V. S. (1997) Synapse 26, 235-242[CrossRef][Medline] [Order article via Infotrieve]
  17. Laufer, R., and Changeux, J.-P. (1989) J. Biol. Chem. 264, 2683-2689[Abstract/Free Full Text]
  18. Kawase, T., Howard, G. A., Roos, B. A., and Burns, D. M. (1995) Bone 16, 379S-384S[CrossRef][Medline] [Order article via Infotrieve]
  19. Drissi, H., Lieberherr, M., Marie, P. J., and Lasmoles, F. (1997) J. Bone Miner. Res. 12, Suppl. 1, F391
  20. Goltzman, D., and Mitchell, J. (1985) Science 227, 1343-1345[Medline] [Order article via Infotrieve]
  21. Stangl, D, Muff, R., Schmolck, C., and Fischer, J. A. (1993) Endocrinology 132, 744-750[Abstract]
  22. Offermanns, S., lida-Klein, A., Segre, G. V., and Simon, M. I. (1996) Mol. Endocrinol. 10, 566-574[Abstract]
  23. Freissmuth, M., Casey, P. J., and Gilman, A. G. (1989) FASEB J. 3, 2125-2131[Abstract/Free Full Text]
  24. Neer, E. J. (1995) Cell 80, 249-257[Medline] [Order article via Infotrieve]
  25. Exton, J. H. (1996) Annu. Rev. Pharmacol. Toxicol. 36, 481-509[CrossRef][Medline] [Order article via Infotrieve]
  26. Ui, M. (1990) in ADP-Ribosylating Toxins and G-Proteins (Moss, J., and Vaugham, M., eds), pp. 45-77, American Society for Microbiology, Washington, D. C.
  27. Martin, T. F. J. (1991) Pharmacol. Ther. 49, 329-345[Medline] [Order article via Infotrieve]
  28. Smrcka, A. V., Hepler, J. R., Brown, K. O., and Sternweis, P. C. (1991) Science 251, 804-807[Medline] [Order article via Infotrieve]
  29. Noh, D.-Y., Shin, S. H., and Ree, S. G. (1995) Biochim. Biophys. Acta 1242, 99-114[CrossRef][Medline] [Order article via Infotrieve]
  30. Lee, C. W., Lee, K. H., Lee, S. B., Park, D., and Rhee, S. G. (1994) J. Biol. Chem. 269, 25335-25338[Abstract/Free Full Text]
  31. Kozasa, T., Hepler, J. R., Smrcka, A. V., Simon, M. I., Rhee, S. G., Sternweis, P. C., and Gilman, A. G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9176-9180[Abstract]
  32. Rhee, S. G., and Choi, K. D. (1992) J. Biol. Chem. 267, 12393-12396[Free Full Text]
  33. Conklin, B. R., and Bourne, H. R. (1993) Cell 73, 631-641[Medline] [Order article via Infotrieve]
  34. Taylor, S. J., Chae, H. Z., Rhee, S. G., and Exton, J. H. (1991) Nature 350, 516-517[CrossRef][Medline] [Order article via Infotrieve]
  35. Camps, M., Carozzi, A., Schabel, P., Scherr, A., Parker, P. J., and Gierschick, P. (1992) Nature 360, 684-686[CrossRef][Medline] [Order article via Infotrieve]
  36. Carozzi, A., Camps, M., Gierschick, P., and Parker, P. J. (1993) FEBS Lett. 315, 340-342[CrossRef][Medline] [Order article via Infotrieve]
  37. Birnbaumer, L., and Birbaumer, M. (1995) J. Recept. Signal Transduct. Res. 15, 213-252[Medline] [Order article via Infotrieve]
  38. Allgeier, A., Offermanns, Van Sande, J., Spicher, K., Schultz, G., and Dumont, J. E. (1994) J. Biol. Chem. 269, 13733-13735[Abstract/Free Full Text]
  39. James, S. R., Varizi, C., Walker, T. R., Milligan, G., and Downes, C. P. (1994) Biochem. J. 304, 359-364[Medline] [Order article via Infotrieve]
  40. Fournier, B., and Price, P. A. (1991) J. Cell Biol. 114, 577-583[Abstract]
  41. Grynkiewicz, G., Poenie, M., and Tsien, R. Y. (1985) J. Biol. Chem. 260, 3440-3450[Abstract]
  42. Prentki, M., Deeney, J. T., Matschinsky, F. M., and Joseph, S. K. (1986) FEBS Lett. 197, 285-288[CrossRef][Medline] [Order article via Infotrieve]
  43. Bleasdale, J. E., Bundy, G. L., Bunting, S., and Fitzpatrick, F. A. (1989) Adv. Prostanglandin Thromboxane Leukotriene Res. 19, 590-593
  44. Le Mellay, V., Grosse, B., and Lieberherr, M. (1997) J. Biol. Chem. 272, 11902-11907[Abstract/Free Full Text]
  45. Bradford, M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  46. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  47. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354[Abstract]
  48. Hofmann, S. L., and Majerus, P. W. (1982) J. Biol. Chem. 257, 14359-13564[Free Full Text]
  49. Wu, D., Lee, C. H., Rhee, S. G., and Simon, M. I. (1992) J. Biol. Chem. 267, 1811-1817[Abstract/Free Full Text]
  50. Berridge, M. J., and Irvine, R. F. (1989) Nature 341, 197-205[CrossRef][Medline] [Order article via Infotrieve]
  51. Joseph, S. K., and Williamson, J. R. (1989) Arch. Biochem. Biophys. 273, 1-15[Medline] [Order article via Infotrieve]
  52. Tanaka, O., and Kondo, H. (1994) Neurosci. Lett. 82, 17-20
  53. Nelson, M. T., Huang, Y., Brayden, J. E., Hescheler, J., and Standen, N. B. (1990) Nature 344, 770-773[CrossRef][Medline] [Order article via Infotrieve]
  54. Kuppe, A., Hedberg, K. K., Volwerk, J. J., and Griffith, O. H. (1990) Biochim. Biophys. Acta 1047, 41-48[Medline] [Order article via Infotrieve]
  55. Singer, W. D., Brown, H. A., and Sternweis, P. C. (1997) Annu. Rev. Biochem. 66, 475-509[CrossRef][Medline] [Order article via Infotrieve]
  56. Strathmann, M. P., and Simon, M. I. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9113-9117[Abstract]
  57. Simon, M. I., Strathmann, M. P., and Gautum, N. (1991) Science 252, 802-808[Medline] [Order article via Infotrieve]
  58. Gudermann, T., Kalkbrenner, F., and Schultz, G. (1996) Annu. Rev. Pharmacol. Toxicol. 36, 429-459[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.